Thomas B. Neff

3.5k total citations
22 papers, 1.7k citations indexed

About

Thomas B. Neff is a scholar working on Hematology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Thomas B. Neff has authored 22 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Thomas B. Neff's work include Erythropoietin and Anemia Treatment (12 papers), Iron Metabolism and Disorders (6 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (5 papers). Thomas B. Neff is often cited by papers focused on Erythropoietin and Anemia Treatment (12 papers), Iron Metabolism and Disorders (6 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (5 papers). Thomas B. Neff collaborates with scholars based in United States, Italy and Germany. Thomas B. Neff's co-authors include Anatole Besarab, Kin-Hung P. Yu, Stefan Hemmerich, Robert Provenzano, Robert Leong, Tyson Lee, Khalil G. Saikali, Lynda A. Szczech, Lona Poole and Stephen J. Klaus and has published in prestigious journals such as Journal of Clinical Oncology, Journal of the American Society of Nephrology and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Thomas B. Neff

22 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas B. Neff United States 12 797 439 406 372 361 22 1.7k
Kin-Hung P. Yu United States 8 605 0.8× 304 0.7× 246 0.6× 171 0.5× 259 0.7× 19 1.1k
Robert Leong United States 9 683 0.9× 322 0.7× 271 0.7× 130 0.3× 293 0.8× 14 954
MA Goldberg United States 14 868 1.1× 267 0.6× 36 0.1× 390 1.0× 333 0.9× 24 1.6k
E. Fritz Austria 23 1.9k 2.4× 109 0.2× 86 0.2× 910 2.4× 671 1.9× 46 2.8k
Tyson Lee United States 7 313 0.4× 207 0.5× 195 0.5× 173 0.5× 149 0.4× 10 670
Paula Buendía Spain 20 299 0.4× 122 0.3× 365 0.9× 384 1.0× 49 0.1× 24 1.3k
Elisa Menegatti Italy 21 171 0.2× 46 0.1× 272 0.7× 260 0.7× 115 0.3× 76 1.3k
Federica Delaini Italy 22 749 0.9× 45 0.1× 281 0.7× 809 2.2× 1.0k 2.8× 48 2.0k
Kazuma Iekushi Japan 22 129 0.2× 192 0.4× 74 0.2× 488 1.3× 147 0.4× 43 1.3k
Constance C. F. M. J. Baaten Netherlands 19 560 0.7× 52 0.1× 103 0.3× 166 0.4× 87 0.2× 34 1.1k

Countries citing papers authored by Thomas B. Neff

Since Specialization
Citations

This map shows the geographic impact of Thomas B. Neff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas B. Neff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas B. Neff more than expected).

Fields of papers citing papers by Thomas B. Neff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas B. Neff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas B. Neff. The network helps show where Thomas B. Neff may publish in the future.

Co-authorship network of co-authors of Thomas B. Neff

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas B. Neff. A scholar is included among the top collaborators of Thomas B. Neff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas B. Neff. Thomas B. Neff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Provenzano, Robert, Lynda A. Szczech, Robert Leong, et al.. (2021). Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non–Dialysis-Dependent CKD. Clinical Journal of the American Society of Nephrology. 16(8). 1190–1200. 56 indexed citations
2.
Provenzano, Robert, Evgeny Shutov, Lona Poole, et al.. (2021). Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrology Dialysis Transplantation. 36(9). 1717–1730. 85 indexed citations
3.
Balzo, Ughetta del, Pierre Signore, Gail Walkinshaw, et al.. (2020). Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease. Journal of Pharmacology and Experimental Therapeutics. 374(2). 342–353. 47 indexed citations
4.
5.
Richeldi, Luca, Evans R. Fernández Pérez, Ulrich Costabel, et al.. (2019). Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet Respiratory Medicine. 8(1). 25–33. 215 indexed citations
6.
Richeldi, Luca, Evans R. Fernández Pérez, Ulrich Costabel, et al.. (2019). Pamrevlumab (FG-3019), an Anti-Connective Tissue Growth Factor Therapy for Idiopathic Pulmonary Fibrosis: A Randomized, Double-Blind, Placebo-Controlled Trial. SSRN Electronic Journal. 1 indexed citations
7.
8.
Seeley, Todd, Mark D. Sternlicht, Stephen J. Klaus, Thomas B. Neff, & David Y. Liu. (2017). Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer. PubMed. Volume 5. 1–9. 45 indexed citations
9.
Picozzi, Vincent J., Flavio G. Rocha, Scott Helton, et al.. (2017). Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ± pamrevlumab (P) as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).. Journal of Clinical Oncology. 35(4_suppl). 365–365. 8 indexed citations
10.
Picozzi, Vincent J., J. Marc Pipas, Albert C. Koong, et al.. (2016). FG-3019, A Human Monoclonal Antibody to Connective Tissue Growth Factor, Combined with Chemotherapy in Patients with Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma. 2(1). 1–8. 8 indexed citations
11.
12.
Picozzi, Vincent J., Flavio G. Rocha, Scott Helton, et al.. (2016). Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ±FG-3019 as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).. Journal of Clinical Oncology. 34(4_suppl). 457–457. 2 indexed citations
13.
Raghu, Ganesh, Mary Beth Scholand, João A. de Andrade, et al.. (2016). FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis. European Respiratory Journal. 47(5). 1481–1491. 140 indexed citations
14.
Besarab, Anatole, Е. А. Chernyavskaya, Evgeny Shutov, et al.. (2015). Roxadustat (FG-4592). Journal of the American Society of Nephrology. 27(4). 1225–1233. 210 indexed citations
15.
Besarab, Anatole, Robert Provenzano, Joachim Hertel, et al.. (2015). Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrology Dialysis Transplantation. 30(10). 1665–1673. 232 indexed citations
16.
Raghu, Ganesh, Mary Beth Scholand, João A. de Andrade, et al.. (2012). Phase 2 trial of FG-3019, anti-CTGF monoclonal antibody, in idiopathic pulmonary fibrosis (IPF): Preliminary safety and efficacy results. 40. 2819. 5 indexed citations
17.
Provenzano, Robert, James A. Tumlin, Raja I. Zabaneh, et al.. (2011). 254 Pharmacokinetics of Oral FG-4592 to Treat Anemia in Hemodialysis (HD) Patients (PTS). American Journal of Kidney Diseases. 57(4). B80–B80. 2 indexed citations
18.
Heestand, Gregory M., J. Marc Pipas, Frank H. Valone, et al.. (2011). A phase I trial of the monoclonal antibody FG-3019 to connective tissue growth factor (CTGF) in locally advanced or metastatic pancreatic cancer.. Journal of Clinical Oncology. 29(4_suppl). 269–269. 6 indexed citations
19.
Adler, Sharon G., Sherwyn Schwartz, Mark E. Williams, et al.. (2010). Phase 1 Study of Anti-CTGF Monoclonal Antibody in Patients with Diabetes and Microalbuminuria. Clinical Journal of the American Society of Nephrology. 5(8). 1420–1428. 171 indexed citations
20.
Provenzano, Robert, et al.. (2008). 212: FG2216, A Novel Oral HIF-PHI, Stimulates Erythropoiesis and Increases Hemoglobin Concentration in Patients with Non-Dialysis CKD. American Journal of Kidney Diseases. 51(4). B80–B80. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kin-Hung P. Yu Breakdown of academic impact, for papers by Robert Leong Breakdown of academic impact, for papers by MA Goldberg Breakdown of academic impact, for papers by E. Fritz Breakdown of academic impact, for papers by Tyson Lee Breakdown of academic impact, for papers by Paula Buendía Breakdown of academic impact, for papers by Elisa Menegatti Breakdown of academic impact, for papers by Federica Delaini Breakdown of academic impact, for papers by Kazuma Iekushi Breakdown of academic impact, for papers by Constance C. F. M. J. Baaten
Rankless by CCL
2026